If neurohormonal dysfunction plays a role in arrhythmogenesis and SCD in HD patients, aldosterone receptor blockade might modify the CV risk, as the Randomized Aldactone Evaluation Study [33] and Dialysis Outcomes Heart Failure Aldactone Study [34] previously reported, and the CV risk may be controlled by NT-proBNP and QTc-driven management strategies. This evidence concerns the gene NR3C2 and heart failure.